• Sanofi’s Dupixent 'rapidly' improves lung function in children pharmatimes
    May 18, 2021
    Sanofi’s Dupixent significantly reduced severe asthma attacks and rapidly improved lung function in children aged six to 11 years old with uncontrolled moderate-to-severe asthma, according to detailed results from a Phase III trial.
PharmaSources Customer Service